Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?

While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.

    Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?

    Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.

      What's in the Cards for BioMarin (BMRN) in Q1 Earnings?

      BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales. On the call, management is likely to comment on the launch preparation for pegvaliase.

        Is a Beat in Store for Vertex (VRTX) This Earnings Season?

        Vertex (VRTX) is expected to beat estimates when it reports its Q1 earnings on Apr 26.

          Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

          Roche (RHHBY) announces encouraging data on multiple sclerosis (MS) drug Ocrevus which reinforced the efficacy of drug in the long run.

            Novartis (NVS) Reports Encouraging Data on MS Candidate

            Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

              Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards?

              While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

                Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline

                The FDA approval for Agios' (AGIO) only marketed drug, Idhifa, augurs well for long-term growth. The company is also well on progress track with its lead candidate, ivosidenib, for R/R AML.

                  Alexion (ALXN) to Acquire Wilson Therapeutics for $855M

                  Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.

                    Celgene (CELG) President and COO to Step Down: What's Ahead?

                    Celgene's (CELG) president and chief operating officer, Scott A. Smith, has decided to step down from his position with immediate effect further adding to the company's woes.

                      Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate

                      Celgene's (CELG) stock was up by 3% after the company announced a co-promotion agreement with bluebird bio for one of its leading CAR-T candidates.

                        Celgene Loses 17.8% in 3 Months: Time to Reshuffle Portfolio?

                        Things have not been going Celgene's (CELG) way as the company has suffered a series of setbacks. The stock has lost 17.8% in the last three months.

                          3 Sell-Rated Drug Stocks Investors Should Avoid for Now

                          Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.

                            Biotech Stock RoundUp: ALXN & ARNA Up on Study Data, PRTA Teams Up With Celgene

                            The biotech sector was in focus last week with Alexion gaining on positive data on PNH candidate, Arena surges on ulcerative drug data, Solid Biosciences' stock suffering a crash and Prothena teaming up with Celgene.

                              Prothena Rallies on Multi-Year Collaboration With Celgene

                              Shares of Prothena (PRTA) surged significantly after the company announced a multi-year collaboration with leading company Celgene to develop new therapies for a broad range of neurodegenerative diseases.

                                The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene

                                The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene

                                  Why Multiple Sclerosis is a Promising but Risky Space?

                                  Multiple Sclerosis (MS) is a promising space but risks continue to persist with the recent withdrawal of Zinbryta.

                                    Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

                                    Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

                                      Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

                                      Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

                                        Pharmaceutical Industry Outlook - March 2018

                                        The year 2017 was rewarding for pharma and biotech stocks, with the sector witnessing some positive developments that led to a much-awaited recovery.

                                          Biotech ETFs Head to Head: XBI vs. IBB.

                                          Head-to-head comparison of two Biotech ETFs, XBI and IBB.

                                            Biotech Stock Round Up: Celgene Suffers Setback, Gilead Teams Up with Sangamo

                                            The major news in the biotech sector in the last five trading sessions include the FDA's refusal to file letter for Celgene Corporation's (CELG) ozanimod while Gilead Sciences, Inc.'s (GILD) announced an agreement with Sangamo Therapeutics.

                                              Sweta Killa headshot

                                              Biotech Crushing the Market: Best ETFs & Stocks YTD

                                              The recent developments are fueling growth in the biotech companies, leading to a rally in their share prices and impressive levels of momentum in biotech ETFs.

                                                Celgene (CELG) Down 8.4% Since Earnings Report: Can It Rebound?

                                                Celgene (CELG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Merck to Buy Australian Firm to Boost Immunotherapy Pipeline

                                                  Merck (MRK) to buy Australian oncolytic immunotherapies maker Viralytics Limited to strengthen its presence in the fast growing immuno-oncology market.